The Survival of Transplant Ineligible Multiple Myeloma Patients Treated with Bortezomib-Based Chemotherapy Is Affected By the Patient Fitness

ConclusionUnfit and frail patients showed a significant decrease in OS compared to fit patients. But there was no difference between the unfit and fit patients in terms of response rate in patients with transplant ineligible MM patients who have received bortezomib-containing regimen. Treatment of the unfit and frail patients needs more caution on toxicity management and appropriate dosing schedules to improve the survival outcome.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - Category: Hematology Authors: Tags: 653. Myeloma: Therapy, excluding Transplantation: Poster II Source Type: research